Twist Bioscience (TWST) Competitors $49.79 +0.62 (+1.26%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$50.06 +0.27 (+0.54%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TWST vs. BEAM, VCYT, DNA, SMMT, and BBIOShould you buy Twist Bioscience stock or one of its competitors? MarketBeat compares Twist Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Twist Bioscience include Beam Therapeutics (BEAM), Veracyte (VCYT), Ginkgo Bioworks (DNA), Summit Therapeutics (SMMT), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector. TWST vs. BEAMTWST vs. VCYTTWST vs. DNATWST vs. SMMTTWST vs. BBIOHow does Twist Bioscience compare to Beam Therapeutics?Twist Bioscience (NASDAQ:TWST) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Is TWST or BEAM more profitable? Twist Bioscience has a net margin of -19.85% compared to Beam Therapeutics' net margin of -39.66%. Twist Bioscience's return on equity of -26.73% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-19.85% -26.73% -19.15% Beam Therapeutics -39.66%-29.00%-22.61% Which has more volatility & risk, TWST or BEAM? Twist Bioscience has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market. Do institutionals and insiders believe in TWST or BEAM? 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend TWST or BEAM? Twist Bioscience currently has a consensus target price of $56.57, indicating a potential upside of 13.62%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 74.69%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Beam Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has higher earnings and valuation, TWST or BEAM? Twist Bioscience has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$376.57M8.23-$77.67M-$1.33N/ABeam Therapeutics$139.74M19.74-$79.99M-$0.68N/A Does the media refer more to TWST or BEAM? In the previous week, Beam Therapeutics had 14 more articles in the media than Twist Bioscience. MarketBeat recorded 21 mentions for Beam Therapeutics and 7 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.64 beat Beam Therapeutics' score of -0.26 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBeam Therapeutics beats Twist Bioscience on 9 of the 17 factors compared between the two stocks.How does Twist Bioscience compare to Veracyte?Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Which has higher valuation and earnings, VCYT or TWST? Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$517.15M6.40$66.35M$1.0938.07Twist Bioscience$376.57M8.23-$77.67M-$1.33N/A Does the media refer more to VCYT or TWST? In the previous week, Twist Bioscience had 2 more articles in the media than Veracyte. MarketBeat recorded 7 mentions for Twist Bioscience and 5 mentions for Veracyte. Veracyte's average media sentiment score of 0.68 beat Twist Bioscience's score of 0.64 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, VCYT or TWST? Veracyte has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market. Do analysts rate VCYT or TWST? Veracyte presently has a consensus target price of $44.83, indicating a potential upside of 8.03%. Twist Bioscience has a consensus target price of $56.57, indicating a potential upside of 13.62%. Given Twist Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Veracyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is VCYT or TWST more profitable? Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Veracyte16.25% 9.07% 8.38% Twist Bioscience -19.85%-26.73%-19.15% SummaryVeracyte beats Twist Bioscience on 8 of the 14 factors compared between the two stocks.How does Twist Bioscience compare to Ginkgo Bioworks?Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Do analysts recommend TWST or DNA? Twist Bioscience presently has a consensus price target of $56.57, indicating a potential upside of 13.62%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential upside of 15.38%. Given Ginkgo Bioworks' higher probable upside, analysts plainly believe Ginkgo Bioworks is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Ginkgo Bioworks 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Do insiders and institutionals believe in TWST or DNA? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is TWST or DNA more profitable? Twist Bioscience has a net margin of -19.85% compared to Ginkgo Bioworks' net margin of -215.41%. Twist Bioscience's return on equity of -26.73% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-19.85% -26.73% -19.15% Ginkgo Bioworks -215.41%-56.08%-26.06% Which has more volatility and risk, TWST or DNA? Twist Bioscience has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Does the media favor TWST or DNA? In the previous week, Twist Bioscience had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 7 mentions for Twist Bioscience and 3 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.64 beat Ginkgo Bioworks' score of -0.40 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has preferable earnings & valuation, TWST or DNA? Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$376.57M8.23-$77.67M-$1.33N/AGinkgo Bioworks$170.15M2.83-$312.76M-$5.36N/A SummaryTwist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.How does Twist Bioscience compare to Summit Therapeutics?Twist Bioscience (NASDAQ:TWST) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Which has more risk and volatility, TWST or SMMT? Twist Bioscience has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.25, meaning that its share price is 225% less volatile than the broader market. Do analysts prefer TWST or SMMT? Twist Bioscience presently has a consensus price target of $56.57, suggesting a potential upside of 13.62%. Summit Therapeutics has a consensus price target of $27.58, suggesting a potential upside of 72.18%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Summit Therapeutics 2 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do institutionals & insiders have more ownership in TWST or SMMT? 4.6% of Summit Therapeutics shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TWST or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-19.85% -26.73% -19.15% Summit Therapeutics N/A -291.24%-243.07% Does the media favor TWST or SMMT? In the previous week, Twist Bioscience had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 7 mentions for Twist Bioscience and 1 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.07 beat Twist Bioscience's score of 0.64 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, TWST or SMMT? Twist Bioscience has higher revenue and earnings than Summit Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$376.57M8.23-$77.67M-$1.33N/ASummit TherapeuticsN/AN/A-$1.08B-$1.60N/A SummaryTwist Bioscience and Summit Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.How does Twist Bioscience compare to BridgeBio Pharma?Twist Bioscience (NASDAQ:TWST) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Does the media prefer TWST or BBIO? In the previous week, BridgeBio Pharma had 12 more articles in the media than Twist Bioscience. MarketBeat recorded 19 mentions for BridgeBio Pharma and 7 mentions for Twist Bioscience. BridgeBio Pharma's average media sentiment score of 0.72 beat Twist Bioscience's score of 0.64 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of TWST or BBIO? 99.9% of BridgeBio Pharma shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TWST or BBIO more profitable? Twist Bioscience has a net margin of -19.85% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-19.85% -26.73% -19.15% BridgeBio Pharma -124.42%N/A -65.81% Do analysts prefer TWST or BBIO? Twist Bioscience presently has a consensus price target of $56.57, suggesting a potential upside of 13.62%. BridgeBio Pharma has a consensus price target of $88.19, suggesting a potential upside of 35.01%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75BridgeBio Pharma 1 Sell rating(s) 0 Hold rating(s) 24 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has preferable valuation & earnings, TWST or BBIO? Twist Bioscience has higher earnings, but lower revenue than BridgeBio Pharma. Twist Bioscience is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$376.57M8.23-$77.67M-$1.33N/ABridgeBio Pharma$502.08M25.48-$724.93M-$3.74N/A Which has more risk & volatility, TWST or BBIO? Twist Bioscience has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. SummaryBridgeBio Pharma beats Twist Bioscience on 11 of the 16 factors compared between the two stocks. Get Twist Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TWST vs. The Competition ExportMetricTwist BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06B$3.31B$6.25B$12.29BDividend YieldN/A2.34%2.80%5.30%P/E Ratio-37.4418.1320.8625.23Price / Sales8.23275.82552.5780.03Price / CashN/A55.2727.4837.30Price / Book6.356.579.676.63Net Income-$77.67M$24.35M$3.56B$335.59M7 Day Performance-11.01%-2.53%-1.67%-1.20%1 Month Performance-16.75%-3.55%-2.63%-1.16%1 Year Performance63.84%53.51%30.05%28.10% Twist Bioscience Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TWSTTwist Bioscience2.2676 of 5 stars$49.79+1.3%$56.57+13.6%+61.0%$3.06B$376.57MN/A990Gap UpBEAMBeam Therapeutics3.5365 of 5 stars$31.75-1.8%$47.17+48.6%+49.9%$3.33B$139.74MN/A510VCYTVeracyte2.4088 of 5 stars$39.70-1.8%$44.83+12.9%+42.1%$3.23B$517.15M36.42790DNAGinkgo Bioworks1.8391 of 5 stars$8.65-3.1%$8.50-1.8%-7.0%$552.98M$151.40MN/A640SMMTSummit Therapeutics3.0743 of 5 stars$18.66+3.2%$27.58+47.8%-32.9%$14.03BN/AN/A110Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Beam Therapeutics Alternatives Veracyte Alternatives Ginkgo Bioworks Alternatives Summit Therapeutics Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Axsome Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Arrowhead Pharmaceuticals Alternatives Abivax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TWST) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Twist Bioscience Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Twist Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
